These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 7273001

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
    Grant S, Rauscher F, Jakubowski A, Cadman E.
    Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A, Anderson LW, Strong J, Cysyk RL.
    J Biol Chem; 1983 Nov 25; 258(22):13564-9. PubMed ID: 6417130
    [Abstract] [Full Text] [Related]

  • 5. Properties of single-step mutants of Syrian hamster cell lines resistant to N-(phosphonacetyl)-L-aspartate.
    Zieg J, Clayton CE, Ardeshir F, Giulotto E, Swyryd EA, Stark GR.
    Mol Cell Biol; 1983 Nov 25; 3(11):2089-98. PubMed ID: 6656764
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK, Inouye T, Goldin A, Stark GR.
    Cancer Res; 1976 Aug 25; 36(8):2720-5. PubMed ID: 1064466
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. m-AMSA and PALA: two new agents in cancer chemotherapy.
    Rozencweig M, Von Hoff DD, Cysyk RL, Muggia FM.
    Cancer Chemother Pharmacol; 1979 Aug 25; 3(3):135-41. PubMed ID: 393427
    [Abstract] [Full Text] [Related]

  • 9. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
    Kensler TW, Erlichman C, Jayaram HN, Tyagi AK, Ardalan B, Cooney DA.
    Cancer Treat Rep; 1980 Aug 25; 64(8-9):967-73. PubMed ID: 7448831
    [Abstract] [Full Text] [Related]

  • 10. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
    Chadwick M, Silveira DM, MacGregor JA, Branfman AR, Liss RH, Yesair DW.
    Cancer Res; 1982 Feb 25; 42(2):627-32. PubMed ID: 7055806
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
    Sharma A, Straubinger NL, Straubinger RM.
    Pharm Res; 1993 Oct 25; 10(10):1434-41. PubMed ID: 8272404
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC, Howell SB.
    Cancer Res; 1985 Aug 25; 45(8):3598-604. PubMed ID: 4016741
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
    Ardalan B, Glazer RI, Kensler TW, Jayaram HN, Van Pham T, Macdonald JS, Cooney DA.
    Biochem Pharmacol; 1981 Aug 01; 30(15):2045-9. PubMed ID: 7295324
    [No Abstract] [Full Text] [Related]

  • 17. Overproduction of the first three enzymes of pyrimidine nucleotide biosynthesis in Drosophila cells resistant to N-phosphonacetyl-L-aspartate.
    Laval M, Azou Y, Giorgi D, Rosset R.
    Exp Cell Res; 1986 Apr 01; 163(2):381-95. PubMed ID: 2869965
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
    Loo TL, Friedman J, Moore EC, Valdivieso M, Marti JR, Stewart D.
    Cancer Res; 1980 Jan 01; 40(1):86-90. PubMed ID: 7349907
    [Abstract] [Full Text] [Related]

  • 19. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
    Friedman J, Moore EC, Hall SW, Loo TL.
    Cancer Treat Rep; 1979 Jan 01; 63(1):85-8. PubMed ID: 421235
    [Abstract] [Full Text] [Related]

  • 20. Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability.
    Cillo C, Ling V, Hill RP.
    Int J Cancer; 1989 Jan 15; 43(1):107-11. PubMed ID: 2910823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.